Veraxa Biotech Holding AGVRXA
13F holders, Q2 2026 (June 30)8holders
$1.24avg. 13F price*
At the end of Q2 2026, 8 institutions reported holding Veraxa Biotech Holding AG (VRXA) in their 13F filings. The largest holders were UBS Group AG ($296K), Geode Capital Management, LLC ($225K) and HRT Financial LP ($35K).
- Company
- Veraxa Biotech Holding AG
- CUSIP
- H9130A103
- Latest filing quarter
- Q2 2026
Total Exit/New Position Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $600K |
| Exits | 0 | $0 |
Ownership 8 holders
| UBS Group AG | 0.00% | New | 157,237 | $296K |
| Geode Capital Management, LLC | 0.00% | New | 119,767 | $225K |
| HRT Financial LP | 0.00% | New | 18,874 | $35K |
| Susquehanna International Group, LLP | 0.00% | New | 10,833 | $20K |
| Picton Mahoney Asset Management | 0.00% | New | 175,000 | $19K |
| Wolverine Asset Management LLC | 0.00% | New | 1,748 | $3K |
| JPMorgan Chase & Co. | 0.00% | New | 396 | $859 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 6 | $11 |
"% of holder's portfolio" is VRXA's weight in each manager's 13F, not the share of Veraxa Biotech Holding AG the manager owns.